Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GPC3-targeted CAR-T in Advanced Hepatocellular Carcinoma
NCT04121273Phase 1Unknown
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Oct 2019
- Primary completion
- Oct 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GPC3-targeted CAR-T cells (Nanjing Drum Tower Hospital) in hepatocellular carcinoma (HCC), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Dose Limiting Toxicity at 2 months. Status: unknown.
02
Drugs
GPC3-targeted CAR-T cells (Nanjing Drum Tower Hospital)
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04121273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04121273.